VIRIDIAN THERAPEUTICS INC (VRDN) Stock News

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 8.42% and 55.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: IOVA

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

Mentions: AMGN

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock